Biodegradable andrographolide-eluting nanofibrous membranes for the treatment of cervical cancer

Figures & data

Figure 1 Chemical structure of andrographolide.

Figure 2 Experimental procedure of the deployment of the andrographolide-eluting membranes.

Notes: (A) A rat bearing the tumor. (B) An incision was made. (C) Implantation of nanofibrous membrane. (D) Wound was closed by sutures.

Figure 3 Scanning electron microscope images and fiber diameter distributions of (A) 6:1 and (B) 3:1 polymer-to-drug ratios.

Figure 4 Water contact angles of (A) pure poly[(d,l)-lactide-co-glycolide] nano-fibers, and (B) 6:1 and (C) 3:1 polymer-to-drug ratio nanofibers.

Figure 5 Tensile properties of electrospun drug-eluting nanofibers.

Abbreviations: AG, andrographolide; PLGA, poly[(d,l)-lactide-co-glycolide].

Figure 6 FTIR spectra of pure PLGA and andrographolide-loaded PLGA nanofibers.

Abbreviations: FTIR, Fourier transform infrared; PLGA, poly[(d,l)-lactide-co-glycolide].

Figure 7 Daily (A) and accumulated release (B) of drug-eluting nanofibers in vitro.

Figure 8 In vivo drug concentrations of andrographolide at the targeted tissue and in the plasma.

Figure 9 Images of the tumors on the backs of the mice.

Notes: A represents as group A; B represents as group B; C represents as group C. 0 represents as day 0; 7 represents as day 7; 14 represents as day 14; 21 represents as day 21; 28 represents as day 28.

Figure 10 Variation of tumor sizes with time.

Notes: *P<0.05 and **P<0.01.

Abbreviations: AG, andrographolide; PLGA, poly[(d,l)-lactide-co-glycolide].

Figure 11 Histological analysis images at days 1–3 (D1–D3).

Notes: Scale bar 1 mm.